Tetracycline Shortage: What Providers and Prescribers Need to Know in 2026

Tetracycline hydrochloride has been part of the prescriber's toolkit since the 1950s. While it has largely been supplanted by doxycycline for most common indications, it remains clinically relevant — particularly for H. pylori eradication with bismuth quadruple therapy, certain acne regimens, and patients with documented doxycycline intolerance. In 2026, supply remains inconsistent and requires proactive prescribing strategies.

Current Availability Status (2026)

Tetracycline is not currently listed on the FDA's active Drug Shortages Database as an ongoing shortage event. Amneal Pharmaceuticals is the primary U.S. generic manufacturer of tetracycline hydrochloride capsules (250 mg and 500 mg). However, the drug has a narrow manufacturing base — effectively one major generic maker — which means any supply disruption would quickly create nationwide availability issues.

At the pharmacy level, many retail and chain pharmacies do not maintain consistent tetracycline inventory due to low prescription volumes. Individual pharmacies may need to special-order the medication, resulting in 1–2 business day delays for patients. ASHP and FDA shortage databases are updated regularly and should be checked before any supply communication to patients.

Shortage History: What Happened and Why

Tetracycline experienced a significant multi-year shortage that affected both dentistry (which uses it for periodontal applications) and medicine broadly. The shortage was attributed to a discontinuance of an active pharmaceutical ingredient. Heritage Pharmaceuticals was the first to re-enter production, but the drug remained on the FDA shortage list even after re-entry — reflecting the time required for supply chains to normalize.

This pattern is common with low-margin generics: when one manufacturer exits, the supply base is insufficient to absorb demand, and rebuilding that manufacturing capacity takes years, not months.

Clinical Indications Where Tetracycline Remains Preferred

While doxycycline has displaced tetracycline in most settings, several clinical scenarios continue to favor tetracycline specifically:

• H. pylori eradication (bismuth quadruple therapy): The 2024 ACG guidelines recommend bismuth quadruple therapy (BQT) as a first-line H. pylori regimen in regions where clarithromycin resistance exceeds 15%. Standard BQT uses tetracycline (not doxycycline) with bismuth, metronidazole, and a PPI for 14 days. Some evidence suggests tetracycline may outperform doxycycline in this context, though substitution is generally considered acceptable if tetracycline is unavailable.
• Acne: Some dermatologists continue to prescribe tetracycline for acne, particularly for patients who have been stable on long-term tetracycline regimens and wish to avoid a switch. For new patients with acne, doxycycline is generally the first-line tetracycline-class antibiotic.
• Rickettsial infections and brucellosis: While doxycycline is the standard of care for rickettsial infections, tetracycline remains a guideline-listed agent for brucellosis (with streptomycin) and some Q fever protocols.

Evidence-Based Alternatives When Tetracycline Is Unavailable

When tetracycline is unavailable, the following substitutions are clinically supported:

• Acne: Doxycycline 50–100 mg BID or minocycline 50–100 mg BID. Both are well-studied and endorsed by AAD guidelines.
• Chlamydia/STIs: Doxycycline 100 mg BID x 7 days is the CDC first-line recommendation and the preferred tetracycline-class treatment.
• H. pylori (BQT): Doxycycline 100 mg BID has been used as a substitute in BQT when tetracycline is unavailable. Data suggest comparable eradication rates when dose and duration are maintained.
• Rickettsial infections: Doxycycline 100 mg BID is the standard of care for Rocky Mountain spotted fever and other rickettsial diseases; tetracycline is rarely preferred in this setting.

Key Prescribing Considerations for Tetracycline

When prescribing tetracycline specifically, ensure patients understand:

• Empty stomach requirement: Tetracycline must be taken at least 1 hour before or 2 hours after meals. Dairy products, antacids, calcium, iron, and zinc all substantially reduce absorption via chelation.
• Dosing frequency: Tetracycline requires 2–4 doses per day, contributing to lower adherence compared to doxycycline (1–2 doses per day).
• Photosensitivity: Tetracyclines increase photosensitivity. Patients should use SPF 30+ and avoid prolonged sun exposure.
• Pregnancy and pediatrics: Contraindicated in pregnancy (Category D) and in children under 8 years due to permanent tooth discoloration and effects on bone development.
• Drug interactions: Anticoagulants (warfarin) may require dose adjustment. Avoid combination with retinoids (isotretinoin, acitretin) due to additive intracranial hypertension risk. Tetracycline antagonizes penicillin — avoid concurrent use.

How to Help Your Patients Access Tetracycline

When prescribing tetracycline, proactively advise patients to check stock before heading to the pharmacy. medfinder for Providers is a resource you can direct patients to — it calls pharmacies near them to identify which ones have their medication in stock.

For a patient-facing version of this update, see our article: Tetracycline Shortage Update: What Patients Need to Know in 2026.